13 February 2024
13 February 2024
What is the outlook for existing approaches and other pharmaceuticals in managing the opioid crisis?
Super Bowl LVIII saw Astellas run awareness for hot flashes and Pfizer touchdown with the history of science.
The latest approval for EOHILIA is based on findings from two clinical trials.
The transaction brings ImmunoGen’s antibody-drug conjugate ELAHERE (mirvetuximab soravtansine-gynx) into AbbVie's portfolio.
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.
The humanised monoclonal antibody DISC-3405 is under investigation in a Phase I clinical trial, with data expected this year.
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events.
The designation was granted based on data from the Phase IIb B-Clear and B-Sure trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
